Brainstorm Cell Therapeutics CFO Resigns, Interim Appointed
Ticker: BCLI · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00005, $35 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, cfo-resignation
TL;DR
CFO out, interim in at Brainstorm Cell Therapeutics. No drama reported.
AI Summary
On April 10, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Dr. Arthur S. Tisch. The company also announced the appointment of Ms. Sharon Roth as interim CFO. The filing indicates that Dr. Tisch's departure is not related to any disagreements with the company's accounting or financial practices.
Why It Matters
The departure of a CFO can signal changes in financial strategy or stability, while the appointment of an interim CFO suggests a transition period for the company's financial leadership.
Risk Assessment
Risk Level: medium — Changes in key financial leadership, even without stated disagreements, can introduce uncertainty regarding financial strategy and operations.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- Dr. Arthur S. Tisch (person) — Resigning Chief Financial Officer
- Ms. Sharon Roth (person) — Appointed Interim Chief Financial Officer
- April 10, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the interim Chief Financial Officer of Brainstorm Cell Therapeutics Inc.?
Ms. Sharon Roth has been appointed as the interim Chief Financial Officer.
What was the effective date of the reported event?
The earliest event reported was on April 10, 2024.
Is the resignation of Dr. Arthur S. Tisch related to any disagreements with the company?
The filing states that Dr. Tisch's departure is not related to any disagreements with the company's accounting or financial practices.
What was Dr. Arthur S. Tisch's role at Brainstorm Cell Therapeutics Inc.?
Dr. Arthur S. Tisch was the Chief Financial Officer of Brainstorm Cell Therapeutics Inc.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-04-11 06:10:22
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
- $35 million — ve business days was below a minimum of $35 million requirement for continued listing on th
Filing Documents
- tm2411567d1_8k.htm (8-K) — 26KB
- tm2411567d1_ex99-1.htm (EX-99.1) — 4KB
- 0001104659-24-046001.txt ( ) — 201KB
- bcli-20240410.xsd (EX-101.SCH) — 3KB
- bcli-20240410_lab.xml (EX-101.LAB) — 33KB
- bcli-20240410_pre.xml (EX-101.PRE) — 22KB
- tm2411567d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, on November 6, 2023, Brainstorm Cell Therapeutics, Inc. (the "Company") received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that, the Company's market value of listed securities over the last 30 consecutive business days was below a minimum of $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the "Minimum Market Value Requirement"). On April 10, 2024, the Company received a letter from Nasdaq that the Company has regained compliance with the Minimum Market Value Requirement and the matter is now closed. On April 11, 2024, the Company issued a press release announcing that the Company has regained compliance with the Minimum Market Value Requirement, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Description No. 99.1 Press Release issued by Brainstorm Cell Therapeutics Inc., dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: April 11, 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer